Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: Results of a phase 3 trial

Blood

Volumn 127, Issue 14, 2016, Pages 1761-1769

  Santagostino, Elena ^a   Martinowitz, Uri ^b   Lissitchkov, Toshko ^c   Pan Petesch, Brigitte ^d   Hanabusa, Hideji ^e   Oldenburg, Johannes ^f   Boggio, Lisa ^g   Negrier, Claude ^h   Pabinger, Ingrid ⁱ   Von Depka Prondzinski, Mario ^j   Altisent, Carmen ^k   Castaman, Giancarlo ^l,m   Yamamoto, Koji ⁿ   Álvarez Roman, Maria Teresa ^o   Voigt, Christine ^p   Blackman, Nicole ^p   Jacobs, Iris ^p  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b SHEBA MEDICAL CENTER   (Israel)

^c Specialised Hospital for Active Treatment Joan Pavel   (Bulgaria)

^d CHU MORVAN   (France)

^e Ogikubo Hospital   (Japan)

^f UNIVERSITY HOSPITAL BONN   (Germany)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITÉ LYON 1   (France)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j Werlhof Institut   (Germany)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l SAN BORTOLO HOSPITAL   (Italy)

^m CAREGGI UNIVERSITY HOSPITAL   (Italy)

ⁿ NAGOYA UNIVERSITY HOSPITAL   (Japan)

^o HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^p CSL BEHRING   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; LONG ACTING DRUG; RECOMBINANT BLOOD CLOTTING FACTOR 9 ALBUMIN FUSION PROTEIN; UNCLASSIFIED DRUG; ALBUMINOID; BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ADULT; ANAPHYLAXIS; ANIMAL CELL; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CHILD; CHRONOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; HEADACHE; HEART PALPITATION; HEMARTHROSIS; HEMOPHILIA B; HUMAN; HYPERSENSITIVITY; INFLUENZA; INFUSION RELATED REACTION; INJECTION SITE REACTION; LANDAU KLEFFNER SYNDROME; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; REDUCTION; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SYNOVITIS; TACHYCARDIA; THROMBOEMBOLISM; BLEEDING; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

ADOLESCENT; ADULT; ALBUMINS; CHILD; FACTOR IX; HEMOPHILIA B; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS;

EID: 84963542247     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-669234     Document Type: Article

References (26)

1. Bolton-Maggs PHB, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801-1809.
2. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47.
3. Baxter Healthcare Corporation. RIXUBIS (package insert). http://www.rixubis.com/pdf/rixubis-pi.pdf. Accessed September 1, 2015.
4. Biogen Idec Inc. ALPROLIX (package insert). http://www.alprolix.com/pdfs/PrescribingInformation.pdf. Accessed September 1, 2015.
5. Powell JS, Pasi KJ, Ragni MV, et al; B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313-2323.
6. Santagostino E, Mancuso ME. Venous access in haemophilic children: choice and management. Haemophilia. 2010;16(suppl 1):20-24.
7. Kuo TT, Baker K, Yoshida M, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol. 2010;30(6):777-789.
8. Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsén L, Ekblad C. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem. 2011;286(7):5234-5241.
9. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost. 2009;102(4):634-644.
10. Nolte MW, Nichols TC, Mueller-Cohrs J, et al. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs. J Thromb Haemost. 2012;10(8):1591-1599.
11. Herzog E, Harris S, Henson C, et al. Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats. Thromb Res. 2014;133(5):900-907.
12. Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012;120(12):2405-2411.
13. Martinowitz U, Lissitchkov T, Lubetsky A, et al. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. Haemophilia. 2015;21(6):784-790.
14. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: guideline for good clinical practice E6 (R1). http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf. Accessed March 23, 2015.
15. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on the clinical investigation of recombinant and human plasma-derived factor IX products. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109691.pdf. Accessed March 23, 2015.
16. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73(2):247-251.
17. Windyga J, Lissitchkov T, Stasyshyn O, et al. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study. Haemophilia. 2014;20(5):651-658.
18. Morfini M, Lee M, Messori A; Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost. 1991;66(3):384-386.
19. Lee M, Morfini M, Schulman S, Ingerslev J; Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Scientific and Standardization Committee communication: the design and analysis of pharmacokinetic studies of coagulation factors. http://c.ymcdn.com/sites/www.isth.org/resource/group/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e/official-communications/fviiipharmaco.pdf. Accessed September 1, 2015.
20. Collins PW, Young G, Knobe K, et al; Paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124(26):3880-3886.
21. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL; Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001;98(13):3600-3606.
22. Martinowitz U, Lubetsky A. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B. Thromb Res. 2013;131(suppl 2):S11-S14.
23. Wyeth Pharmaceuticals Inc. BENEFIX (package insert). http://labeling.pfizer.com/showlabeling.aspx?id5492. Accessed September 1, 2015.
24. Den Uijl IEM, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia. 2011;17(6):849-853.
25. Savage N. Clotting factors: stretching time. Nature. 2014;515(7528):S162-S164.
26. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935-1939.